Abstract: Apparatus and methods are described for determining a property of a bodily sample using a microscope and optical-density-measurement apparatus, the apparatus including a sample carrier that includes a plurality of microscopy sample chambers configured to receive a first portion of the sample and to facilitate imaging of the first portion of the sample by the microscope, each of the microscopy sample chambers having an upper and a lower surface, and having respective heights between the upper and lower surfaces that are different from each other. The sample carrier includes at least one optical-density-measurement chamber configured to receive a second portion of the sample, and to facilitate optical density measurements being performed optical-density-measurement apparatus upon the second portion of the sample. Other applications are also described.

Abstract: The disclosed embodiments include a system and method for generating a predictive model for determining whether a reamer has experienced significant wear. The system includes an information acquisition processor and a server. The information acquisition processor retrieves wellbore information, transmits the information to the server.

Abstract: Apparatus and methods are described including a sample carrier (22) configured to carry a portion of a bodily sample, at least a portion of the sample carrier being configured to fluoresce, at least under certain conditions. An optical measurement device (24) performs optical measurements upon the portion of the bodily sample that is housed within the sample carrier (22), and at least partially photobleaches an area within the portion of the sample carrier (22) by causing the area to fluoresce. By detecting that the area within the portion of the sample carrier (22) has been photobleached, an output is generated indicating that at least a portion of the sample carrier (22) is contaminated or that optical measurements cannot be performed on the portion of the sample carrier (22), or the optical measurement device (24) is prevented from performing optical measurements upon a sample portion housed within the given portion of the sample carrier (22).

Abstract: Systems, methods, and devices for broadcast service negotiation and non-simultaneous transmit-receive (STR) channel blindness recovery are provided herein. Some methods performed by a Wireless Transmit/Receive Unit (WTRU), may comprise operating over a first link; operating over a second link; receiving a frame including a Network Allocation Vector (NAV) setting associated with the second link, the NAV setting indicating a time duration; and sending a transmission over the first link, wherein a duration of the transmission over the first link is shorter than or equal to the time duration indicated by the NAV setting. The frame including the NAV setting indicates that the time duration may not be extended or modified. The method may further comprise sending, by the WTRU, an indication that it the WTRU is capable of performing a multi-link restricted transmission. The WTRU may enter a sleep mode on the first link after sending the transmission over the first link.

Abstract: Systems and methods are provided to implement features in the IEEE 802. 11ad+/ay protocols by utilizing combinations of analog and digital precoding (such as hybrid mmWave precoding) to enable multi-stream/multi-user transmissions. These systems and methods are also suitable for 5G wireless networks, such as found in 3GPP. These systems and methods address performing general precoder design, reducing of beam-training overhead with leak wave antennas, performing single-stage approximate precoding with enhanced SLS for SU-MIMO transmissions (eSLS1), performing multi-stage approximate precoding with enhanced SLS for SU-MIMO transmissions (eSLS2), and performing exact precoding with enhanced SLS for SU-MIMO transmissions.

Abstract: The present invention is directed to a composition comprising phytoene, phytofluene, and zeta carotene, and methods of using the same, such as for reducing collagen loss.

Abstract: A wireless transmit/receive unit (WTRU) may utilize pre-configured rules for scaling power levels. Channels may be grouped based on a type of data to be transmitted. A power level of a channel from a group may be scaled using the pre-configured rules. A power level of a channel of a supplementary carrier may be scaled before another channel of a non-supplementary carrier.

Abstract: The present invention provides a therapeutic composition comprising one or more polyphenols and one or more carotenoids selected from the group consisting of lutein, lycopene and beta-carotene. The invention also provides methods for inhibiting or reducing the production of superoxide ions, NO, TNF-alpha and/or PGE2 in a mammalian subject comprising administering to said subject the aforementioned therapeutic composition.

Abstract: Methods and apparatuses are described herein for HARQ signaling and communications in wireless networks. For example, a method implemented in a STA comprises receiving a first MU transmission including a first set of HARQ bits, a first set of user data for STAs including the STA, a preamble including information indicating that the MU transmission includes the first set of HARQ bits, and a first set of HARQ Process IDs associated with the first set of HARQ bits; determining a subset of HARQ bits of the first set of HARQ bits; transmitting a response message indicating a reception status of the subset of HARQ bits; and receiving a second MU transmission including a second set of HARQ bits, a second set of user data for the plurality of STAs, and a second set of HARQ Process IDs associated with the second set of HARQ bits.

Abstract: The invention is directed to compositions comprising lycopene and to methods of using the same, such as for improving one or more skin parameters, e.g., prevention or treatment of various skin-related conditions caused by ultraviolet radiation.

Abstract: The present invention provides a therapeutic composition comprising heat-treated clear tomato concentrate (CTC), which has been found to possess both anti-inflammatory and bone-health promoting effects. The present invention is also directed to a composition comprising heat-treated CTC in combination with one or more carotenoids.

Abstract: The present invention provides a composition comprising lycopene, one or both of phytoene and phytofluene, and phytosterols, wherein the concentration of lycopene is in the range of 0.3%-2% (w/w) and wherein the weight ratio of said lycopene to one or both of phytoene and phytofluene is in the range of 1:1 to 1:2.5. The invention also encompasses a method for preparing said composition.

Abstract: The present invention provides a therapeutic composition comprising one or more polyphenols and one or more carotenoids selected from the group consisting of lutein, lycopene and beta-carotene. The invention also provides methods for inhibiting or reducing the production of superoxide ions, NO, TNF-alpha and/or PGE2 in a mammalian subject comprising administering to said subject the aforementioned therapeutic composition.

Abstract: This invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of 1) identifying whether the human subject is a predicted responder to glatiramer acetate by determining the genotype of the subject at one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of the SNPs in Group 1; and 2) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.

Abstract: The present invention provides a therapeutic composition comprising heat-treated clear tomato concentrate (CTC), which has been found to possess both anti-inflammatory and bone-health promoting effects. The present invention is also directed to a composition comprising heat-treated CTC in combination with one or more carotenoids.

Abstract: This application provides a method for treating a human subject afflicted with Parkinson's disease (PD) with a pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, and a pharmaceutically acceptable carrier, comprising the steps of: (i) obtaining a biological sample comprising a genome from the human subject afflicted with Parkinson's disease; (ii) assaying the DNA or RNA of the biological sample from the human subject using a probe or a primer, to determine the diploid genotype of the human subject at single nucleotide polymorphism (SNP) rs1076560 or rs2283265; (iii) identifying the human subject as a predicted responder to rasagiline if the diploid genotype is CC at rs1076560, CC at rs2283265, or CC at both rs1076560 and rs2283265; and (iv) administering the pharmaceutical composition comprising rasagiline and a pharmaceutically acceptable carrier to the human subject if the human subject is identified as a predicted responder to rasagiline.

Abstract: An actuator arrangement is disclosed herein for an electronically actuatable door latch that controls a door of a vehicle. The actuator arrangement includes, but is not limited to, an actuating member that is connected to the door and that is operatively coupled to the electronically actuatable door latch. The actuating member is configured to actuate the electronically actuatable door latch when the actuating member is pushed in an outboard direction. The actuator arrangement further includes a bracing member that is mounted to the door proximate the actuating member at a position that is inboard of the actuating member. The bracing member permits a user to brace against the bracing member when pushing the actuating member in an outboard direction.

Abstract: This invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of 1) identifying whether the human subject is a predicted responder to glatiramer acetate by determining the genotype of the subject at one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of the SNPs in Group 1; and 2) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.

Abstract: A system and method for providing dynamic information relay by using geolocational data. Relay of information is triggered by proximity to the geolocation of objects of interest, thereby resulting in dynamic and automated information transmission to a mobile device.